These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 12590236)
41. Massive intestinal bleeding in association with Crohn's disease. Driver CP; Anderson DN; Keenan RA J R Coll Surg Edinb; 1996 Jun; 41(3):152-4. PubMed ID: 8763176 [TBL] [Abstract][Full Text] [Related]
42. Local injection of Infliximab for the treatment of perianal Crohn's disease. Poggioli G; Laureti S; Pierangeli F; Rizzello F; Ugolini F; Gionchetti P; Campieri M Dis Colon Rectum; 2005 Apr; 48(4):768-74. PubMed ID: 15768185 [TBL] [Abstract][Full Text] [Related]
43. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center. Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727 [TBL] [Abstract][Full Text] [Related]
44. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease. de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M Digestion; 2008; 78(4):195-200. PubMed ID: 19122456 [TBL] [Abstract][Full Text] [Related]
45. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431 [TBL] [Abstract][Full Text] [Related]
46. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
48. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. D'haens G; Van Deventer S; Van Hogezand R; Chalmers D; Kothe C; Baert F; Braakman T; Schaible T; Geboes K; Rutgeerts P Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494 [TBL] [Abstract][Full Text] [Related]
49. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
50. Life-threatening hemorrhage and exsanguination from Crohn's disease. Report of four cases. Cirocco WC; Reilly JC; Rusin LC Dis Colon Rectum; 1995 Jan; 38(1):85-95. PubMed ID: 7813353 [TBL] [Abstract][Full Text] [Related]
51. Infliximab aids recovery of anal continence in a patient with perianal Crohn's disease. Caetano C BioDrugs; 2010 Dec; 24 Suppl 1():22-4. PubMed ID: 21175231 [TBL] [Abstract][Full Text] [Related]
58. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252 [TBL] [Abstract][Full Text] [Related]
59. [Anti-TNF therapy in treatment of luminal Crohn's disease]. Marko B; Prka L Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301 [TBL] [Abstract][Full Text] [Related]
60. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Sapienza MS; Cohen S; Dimarino AJ Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]